Phase 2 N=100 Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Advanced Metastatic Cancer · Advanced Prostate Cancer
Primary: Clinical Benefit Rate (CBR) of Nivolumab With or Without Ipilimumab — 1; 18; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=623 Mobile Phone Support for Adults and Support Persons to Live Well With Diabetes
Type 2 Diabetes
Primary: Change in Glycemic Control (Patient Participants) During Intervention Period — 8.64; 8.53; 8.00; 8.31 percent
Phase 2 N=18 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
Leukemia
Primary: Number of Participants With a Response to Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With…
Phase 3 N=492 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Non-small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 5.6; 5.5 Months — p=0.0122
Phase 2 N=65 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Percent Change in the Number of Eosinophils Per High Power Field in Gastric or Duodenal Mucosa From Baseline — -79; -92; -86; 9 Percentage of Change — p=<0.001
N/A N=120 Developing Online Interventions to Reduce Stigma-Related Stress, Sexual Health, and HIV Risk Among Young Chinese MSM
LGBTQ · Sexual Behavior · HIV Risk
Primary: Change in Number of Past 90-Day Condomless Anal Sex Acts — 1.98; 1.80; 0.58; 0.80 condomless anal sex acts
Phase 2 N=10 Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
GLUT1DS1
Primary: Change in Ketosis (Beta-hydroxybutyrate Levels) — 3.82 mM
Phase 2 N=54 Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia With Gene Mutations
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
N/A N=38 Training Induced Muscle Exosome Release
Metabolism
Primary: miR-1 Abundance — 226; 110; 286 percent change
Phase 2 N=11 Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Leukemia
Primary: Overall Response (OR) Post Transplant — 1; 6; 0 Participants
N/A N=3,671 Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
Covid19 · Vaccine Refusal
Primary: Number of Participants Who Received a Booster Vaccination Through the Targeted Visit — 164; 146; 166 Participants
Phase 2 N=204 Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Mixed Dyslipidemia
Primary: Percent Change From Baseline in Fasting TG at Week 24 — 7.55; -43.67; -49.01; -55.57 percentage change — p=<.0001
N/A N=23 Pilot Testing A Pregnancy Decision Making Tool for Women With Spinal Cord Injury (SCI)
Spinal Cord Injuries · Pregnancy Related
Primary: Final Decisional Conflict Scale Score - Values Clarity Sub-scale — 13.4 units on a scale
N/A N=3 Effect of Constraint-Induced Gaming Therapy in an Acute Care Setting
Stroke
Primary: Action Research Arm Test (ARAT) — 37.5; 47 units on a scale
Phase 2 N=119 Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Autoimmune Disorder · Rheumatoid Arthritis · Systemic Lupus Erythematosus
Primary: The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE — 60.0; 33.3 Percentage of participants…